Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ALBIREO

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Phase 3

Completed

Conditions: Alagille Syndrome

Interventions: Drug: Placebo
Drug: Odevixibat

First Posted Date: 2020-12-19

Last Posted Date: 2023-11-02

Lead Sponsor: Albireo

Target Recruit Count: 52

Registration Number: NCT04674761

Locations: 🇺🇸
University of California - San Francisco, San Francisco, California, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

and more 29 locations

Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis

Conditions: Progressive Familial Intrahepatic Cholestasis

First Posted Date: 2020-07-23

Last Posted Date: 2024-03-07

Lead Sponsor: Albireo

Registration Number: NCT04483531

Locations: 🇺🇸
Albireo Pharma Inc., Boston, Massachusetts, United States

A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Phase 2

Completed

Conditions: NAFLD
NASH

Interventions: Drug: Placebo oral tablet
Drug: Elobixibat

First Posted Date: 2019-07-05

Last Posted Date: 2021-09-27

Lead Sponsor: Albireo

Target Recruit Count: 47

Registration Number: NCT04006145

Locations: 🇺🇸
Hope Clinical Research, Canoga Park, California, United States
🇺🇸
Inland Empire Clinical Trials, LLC, Rialto, California, United States
🇺🇸
Peak Gastroenterology Associates, Colorado Springs, Colorado, United States

and more 7 locations

Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: A4250

First Posted Date: 2018-07-31

Last Posted Date: 2024-03-07

Lead Sponsor: Albireo

Target Recruit Count: 17

Registration Number: NCT03608319

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

Phase 3

Completed

Conditions: PFIC2
PFIC1

Interventions: Drug: A4250 (odevixibat)
Drug: Placebo

First Posted Date: 2018-06-25

Last Posted Date: 2021-09-05

Lead Sponsor: Albireo

Target Recruit Count: 62

Registration Number: NCT03566238

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Denver, Colorado, United States

and more 42 locations

An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects

Phase 1

Completed

Conditions: Orphan Cholestatic Liver Diseases
Progressive Familial Intrahepatic Cholestasis
Alagille Syndrome
Primary Biliary Cirrhosis

Interventions: Drug: 3 mg [14C]-A4250 capsule

First Posted Date: 2017-03-17

Last Posted Date: 2024-03-07

Lead Sponsor: Albireo

Target Recruit Count: 6

Registration Number: NCT03082937

Locations: 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

Phase 1

Completed

Conditions: Orphan Cholestatic Liver Diseases
Primary Biliary Cirrhosis
Alagille Syndrome
Progressive Familial Intrahepatic Cholestasis

Interventions: Drug: A4250
Drug: Placebo
Drug: Questran
Drug: CRC (A3384)

First Posted Date: 2016-11-15

Last Posted Date: 2024-03-07

Lead Sponsor: Albireo

Target Recruit Count: 94

Registration Number: NCT02963077

A4250, an IBAT Inhibitor in Pediatric Cholestasis

Phase 2

Completed

Conditions: Pediatric Cholestasis

Interventions: Drug: A4250

First Posted Date: 2015-12-15

Last Posted Date: 2024-03-07

Lead Sponsor: Albireo

Target Recruit Count: 24

Registration Number: NCT02630875

Locations: 🇩🇰
Department of Pediatric and Adolescent Medicine Rigshospitalet, Copenhagen, Denmark
🇫🇷
Pediatric Hepatology and Liver Transplantation, University Hospitals of Paris-Sud, Paris, Orsay, France
🇫🇷
Department of Pediatric Gastroenterology Hepatology-Nutrition, Necker-Enfants maladies hospital, Paris, France

and more 4 locations

Double-blind, Randomised Study of A3384 in BAM/BAD

Phase 2

Completed

Conditions: Bile Acid Malabsorption

Interventions: Drug: A3384

First Posted Date: 2014-03-05

Last Posted Date: 2024-03-07

Lead Sponsor: Albireo

Target Recruit Count: 19

Registration Number: NCT02078856

Locations: 🇸🇪
Sahlgrenska Academy, Göteborg, Sweden
🇸🇪
Kärnsjukhuset, Skövde, Sweden
🇬🇧
Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom

Study of A3309 in Patients With Dyslipidemia

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: A3309
Drug: Placebo

First Posted Date: 2010-02-17

Last Posted Date: 2024-03-07

Lead Sponsor: Albireo

Target Recruit Count: 36

Registration Number: NCT01069783

Locations: 🇸🇪
BCRC, Linköping, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy